Compare ADMA Biologics Inc (ADMA) vs Berkshire Hathaway Inc Class B (BRK.B) Price & Performance

ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.

The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.

BRK.B trades at $495.03, down 2.3% on the day, with a bullish technical signal from moving averages but a neutral stance from oscillators. The stock lacks key valuation ratios like P/E and P/B in the provided data, indicating potential data gaps. Analyst consensus is positive with 57% buy ratings and no sell recommendations.

The outlook remains cautiously optimistic given strong analyst support and bullish technical trends, though overbought RSI levels near 80 suggest short-term consolidation risks. Key risks include market volatility and reliance on broad economic health, but institutional confidence provides a stable foundation.